Clinical Trials Directory

Trials / Terminated

TerminatedNCT00813111

Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation

A Phase 3, Multicenter, Randomized, Double-blind Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Bilateral, Cosmetic Sub-muscular Breast Augmentation

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
136 (actual)
Sponsor
Pacira Pharmaceuticals, Inc · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

Detailed description

This is a phase 3 study conducted to evaluate the safety and efficacy of a single local administration of 300 mg of SKY0402 compared with 100 mg of conventional, commercially-available bupivacaine HCl (i.e. Marcaine 0.5% with epinephrine) administered locally into the implant pocket of each breast for postoperative analgesia in subjects undergoing bilateral, cosmetic, sub-muscular, breast augmentation under general anesthesia (endotracheal or otherwise). A total of 600 mg of SKY0402 or 200 mg bupivacaine HCl per subject is therefore administered. Post-operative assessments were conducted including adverse event and serious adverse event monitoring through Day 30.

Conditions

Interventions

TypeNameDescription
DRUGSKY0402600mg SKY0402 instilled into breast pocket during surgery
DRUGBupivacaine HCl200mg Bupivacaine HCl instilled into breast pocket during surgery

Timeline

Start date
2008-11-01
Primary completion
2009-02-01
Completion
2009-02-01
First posted
2008-12-22
Last updated
2014-01-16
Results posted
2014-01-16

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00813111. Inclusion in this directory is not an endorsement.